Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
Status:
Recruiting
Trial end date:
2029-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate if the combination of drugs, Lenalidomide and
Luspatercept, will help improve the treatment of anemia in patients with lower-risk
Myelodysplastic Syndrome (MDS).